Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > LATEST
LATEST
-
BUSINESS Eisai Settles Lenvima Patent Case with India’s Torrent
November 10, 2025
-
REGULATORY Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
-
REGULATORY Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
-
BUSINESS Nipro, Nichi-Iko to Consolidate Injectable Antibiotics Production by 2026
November 7, 2025
-
BUSINESS Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
-
REGULATORY MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
-
BUSINESS Genmab Seeks Label Expansion for Epkinly Combo Use in Japan
November 7, 2025
-
BUSINESS Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
-
BUSINESS Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
-
BUSINESS Otsuka Launches Global PIII for Drug-Resistant Tuberculosis Therapy
November 7, 2025
-
BUSINESS Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
-
REGULATORY Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
-
REGULATORY Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
-
REGULATORY MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
-
REGULATORY Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
-
REGULATORY Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
-
REGULATORY Tepid Exchanges at Chuikyo over Public-Private Working Group Report
November 6, 2025
-
REGULATORY Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
-
BUSINESS Leqembi Sales Soar 153% in H1 FY2025; Eisai Pins Hopes on Self-Injector, Blood Tests
November 6, 2025
-
REGULATORY Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…